...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Phase 1b/2 trial expected to initiate 1Q 2019

P1,,,,,,may I ask what was the cost per share assigned to the shares coming out of the RRSP and then later going into the TFSA??....RBC noted to me that they would transfer based on the last issued FV letter from Zenith capital which is around (.689 USD) or equivalent .82 cents CAD give or take!

Share
New Message
Please login to post a reply